NO20070189L - Immunoglobuliner - Google Patents

Immunoglobuliner

Info

Publication number
NO20070189L
NO20070189L NO20070189A NO20070189A NO20070189L NO 20070189 L NO20070189 L NO 20070189L NO 20070189 A NO20070189 A NO 20070189A NO 20070189 A NO20070189 A NO 20070189A NO 20070189 L NO20070189 L NO 20070189L
Authority
NO
Norway
Prior art keywords
antibodies
diseases
immunoglobulins
hll
hil
Prior art date
Application number
NO20070189A
Other languages
English (en)
Norwegian (no)
Inventor
Claire Ashman
Jonathan Henry Ellis
Martin John Cassidy
Trevor Anthony Kenneth Wattam
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35521159&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20070189(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0414799.7A external-priority patent/GB0414799D0/en
Priority claimed from GB0423675A external-priority patent/GB0423675D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20070189L publication Critical patent/NO20070189L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20070189A 2004-07-01 2007-01-11 Immunoglobuliner NO20070189L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0414799.7A GB0414799D0 (en) 2004-07-01 2004-07-01 Immunoglobulins
GB0423675A GB0423675D0 (en) 2004-10-25 2004-10-25 Immunoglobulins
PCT/GB2005/002581 WO2006003407A2 (en) 2004-07-01 2005-06-30 Chimeric and humanised monoclonal antibodies against inteleukin- 13

Publications (1)

Publication Number Publication Date
NO20070189L true NO20070189L (no) 2007-03-29

Family

ID=35521159

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070189A NO20070189L (no) 2004-07-01 2007-01-11 Immunoglobuliner

Country Status (26)

Country Link
US (2) US7807788B2 (de)
EP (2) EP1802658B1 (de)
JP (1) JP5102616B2 (de)
KR (1) KR20070034609A (de)
AR (1) AR049565A1 (de)
AT (1) ATE535545T1 (de)
AU (1) AU2005259025B2 (de)
BR (1) BRPI0512826A (de)
CA (1) CA2571799A1 (de)
CY (1) CY1112372T1 (de)
DK (1) DK1802658T3 (de)
ES (2) ES2456897T3 (de)
HR (1) HRP20120139T1 (de)
IL (1) IL180152A0 (de)
MA (1) MA28726B1 (de)
MX (1) MX2007000026A (de)
NO (1) NO20070189L (de)
NZ (1) NZ552063A (de)
PE (1) PE20060376A1 (de)
PL (1) PL1802658T3 (de)
PT (1) PT1802658E (de)
RU (1) RU2404192C2 (de)
SG (1) SG153878A1 (de)
SI (1) SI1802658T1 (de)
TW (1) TWI307630B (de)
WO (1) WO2006003407A2 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0407315D0 (en) 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
KR101073590B1 (ko) * 2003-07-15 2011-10-14 메디뮨 리미티드 Ｉｌ-13에 대한 인간 항체 분자
SG10201404273QA (en) 2003-12-23 2014-10-30 Genentech Inc Novel anti-il 13 antibodies and uses thereof
AR049390A1 (es) 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) 2004-06-17 2009-03-10 Wyeth IL-13 binding agents
JP2008520684A (ja) 2004-11-17 2008-06-19 アブジェニックス・インコーポレーテッド Ｉｌ−１３に対する完全ヒトモノクローナル抗体
US9072716B2 (en) 2005-04-15 2015-07-07 The United States of America, as represented by the Secretary Department of Health by Human Servies Methods of treating and preventing inflammatory bowel disease involving IL-13 and NKT cells
AU2006296399B2 (en) 2005-09-30 2011-01-20 Medimmune Limited Interleukin-13 antibody composition
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
GB0600488D0 (en) * 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
JP2009523460A (ja) * 2006-01-24 2009-06-25 ドマンティス リミテッド Ｉｌ−４および／またはｉｌ−１３に結合するリガンド
CA2914170C (en) 2006-09-08 2018-10-30 Abbvie Bahamas Ltd. Interleukin-13 binding proteins
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN101522716B (zh) * 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
DE102008053503B4 (de) * 2008-10-28 2011-04-28 Justus-Liebig-Universität Giessen Immunologischer Test zum Nachweis von Autoantikörpern gegen testikuläre Antigene
GB0904214D0 (en) 2009-03-11 2009-04-22 Ucb Pharma Sa Biological products
EP2435481A1 (de) * 2009-05-28 2012-04-04 Glaxo Group Limited Il-13-bindendes protein
ES2813398T3 (es) 2009-10-20 2021-03-23 Abbvie Inc Aislamiento y purificación de anticuerpos anti-IL-13 usando cromatografía de afinidad a Proteína A
WO2011119925A2 (en) * 2010-03-25 2011-09-29 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthetic herpes simplex viruses for treatment of cancers
TWI732259B (zh) 2010-12-16 2021-07-01 美商建南德克公司 關於th2抑制作用之診斷及治療
JP6306588B2 (ja) 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
PL2892927T3 (pl) 2012-09-07 2018-11-30 Regeneron Pharmaceuticals, Inc. Sposoby leczenia atopowego zapalenia skóry przez podawanie antagonisty IL-4R
TWI679019B (zh) * 2013-04-29 2019-12-11 法商賽諾菲公司 抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
TWI755763B (zh) 2013-06-04 2022-02-21 美商再生元醫藥公司 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
ES2915378T3 (es) 2013-09-13 2022-06-22 Hoffmann La Roche Procedimientos para detectar y cuantificar una proteína de célula huésped en líneas celulares
EP4331605A3 (de) 2013-09-13 2024-05-22 F. Hoffmann-La Roche AG Verfahren und zusammensetzungen mit gereinigten rekombinanten polypeptiden
SG11201603127WA (en) 2013-10-23 2016-05-30 Genentech Inc Methods of diagnosing and treating eosinophilic disorders
WO2015120171A1 (en) 2014-02-07 2015-08-13 Medimmune, Llc Novel assay to detect human periostin
JP2017507939A (ja) 2014-02-21 2017-03-23 ジェネンテック， インコーポレイテッド 抗ｉｌ−１３／ｉｌ−１７二重特異性抗体及びその使用
KR102695088B1 (ko) 2014-02-28 2024-08-16 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제의 투여에 의한 피부 감염의 치료 방법
EP3129497B1 (de) 2014-04-11 2021-09-08 Novartis AG Verfahren zur selektiven behandlung von asthma mit il-13 antagonisten
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
EP3271723A1 (de) 2015-03-16 2018-01-24 F. Hoffmann-La Roche AG Verfahren für den nachweis und die quantifizierung von il-13 und verwendungen in der diagnostik und behandlung von th2-assoziierten erkrankungen
ITUB20155097A1 (it) * 2015-11-05 2017-05-05 Biouniversa Srl Anticorpi umanizzati anti-BAG3
KR102460040B1 (ko) 2016-04-27 2022-11-01 애브비 인코포레이티드 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법
JP2019527535A (ja) * 2016-05-18 2019-10-03 上海開拓者生物医薬有限公司Ｓｈａｎｇｈａｉ Ｐｈａｒｍａｅｘｐｌｏｒｅｒ Ｃｏ．， Ｌｔｄ． Ｉｌ−１３抗体およびその製造方法と使用
ES2994774T3 (en) 2016-09-01 2025-01-31 Regeneron Pharma Methods for preventing or treating allergy by administering an il-4r antagonist
WO2018057776A1 (en) 2016-09-22 2018-03-29 Regeneron Pharmaceuticals, Inc. Methods for treating severe atopic dermatitis by administering an il-4r inhibitor
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018183932A1 (en) 2017-03-30 2018-10-04 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
KR102694419B1 (ko) 2017-10-30 2024-08-09 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
AU2019218128A1 (en) 2018-02-09 2020-09-17 Genentech, Inc. Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
BR112020020387A2 (pt) 2018-05-13 2021-01-19 Regeneron Pharmaceuticals, Inc. Métodos para o tratamento de dermatite atópica por administração de um inibidor de il-4r
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US20220249814A1 (en) 2018-11-19 2022-08-11 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
JP2022510377A (ja) * 2018-12-03 2022-01-26 デルマタ・セラピューティクス，エルエルシー 状態の処置のための組成物
MA55204A (fr) 2019-03-06 2022-01-12 Regeneron Pharma Inhibiteurs de la voie il-4/il-13 pour une efficacité améliorée dans le traitement du cancer
CN113597328B (zh) 2019-03-21 2025-10-31 瑞泽恩制药公司 用于治疗过敏症的il-4/il-13途径抑制剂和浆细胞消融的组合
WO2021011614A1 (en) 2019-07-16 2021-01-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
JP7836754B2 (ja) 2019-08-05 2026-03-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｉｌ－４ｒアンタゴニストを投与することによりアレルギーを治療しアレルゲン特異的免疫療法を増強するための方法
CN114173816A (zh) 2019-08-05 2022-03-11 瑞泽恩制药公司 通过施用il-4r拮抗剂治疗特应性皮炎的方法
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
AU2022425608A1 (en) 2021-12-30 2024-08-15 Regeneron Pharmaceuticals, Inc. Methods for attenuating atopic march by administering an il-4/il-13 antagonist
EP4227321A1 (de) * 2022-02-10 2023-08-16 AVA Lifescience GmbH Antikörper gegen den b-zell rezeptor chronischer lymphatischer leukämie (cll) zur verwendung bei der behandlung von cll
TW202525846A (zh) 2023-08-25 2025-07-01 美商普羅特歐拉吉克適美國公司 抗ｉｌ—１３多特異性抗體構築體及其用途

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
EP0368684B2 (de) 1988-11-11 2004-09-29 Medical Research Council Klonierung von Immunglobulin sequenzen aus den variabelen Domänen.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
EP0402226A1 (de) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformationsvektoren für Hefe Yarrowia
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
CA2114015C (en) 1991-07-25 2002-12-10 Roland A. Newman Recombinant antibodies for human therapy
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
GB9122820D0 (en) 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
HU225869B1 (en) 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
EP0656064B1 (de) 1992-08-17 1997-03-05 Genentech, Inc. Bispezifische immunoadhesine
AU6852594A (en) 1993-06-03 1995-01-03 Therapeutic Antibodies Inc. Production of antibody fragments
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
EP0957087B1 (de) 1994-06-15 2002-12-04 The Wellcome Foundation Limited Zwischenprodukte verwendbar in der Herstellung von Enzym-Inhibitoren
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
MY117948A (en) 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
DE19723722A1 (de) 1997-05-30 1998-12-10 Schering Ag Nichtsteroidale Gestagene
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
US6506766B1 (en) 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
JP2002506856A (ja) 1998-03-14 2002-03-05 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング フタラジノンｐｄｅｉｉｉ／ｉｖ阻害剤
GB9806530D0 (en) 1998-03-26 1998-05-27 Glaxo Group Ltd Inflammatory mediator
WO1999055369A1 (en) 1998-04-28 1999-11-04 Smithkline Beecham Corporation Monoclonal antibodies with reduced immunogenicity
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
WO2000044407A2 (en) * 1999-02-01 2000-08-03 Amgen Canada Materials and methods to inhibit hodgkin and reed sternberg cell growth
HK1043788A1 (zh) 1999-05-04 2002-09-27 American Home Products Corporation 四環黃體酮受體調節劑化合物及方法
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US6263209B1 (en) 1999-07-28 2001-07-17 Motorola, Inc. Method and apparatus in a wireless communication system for creating a learning function
CO5180649A1 (es) 1999-09-01 2002-07-30 Abbott Lab Antagonistas de los receptores de los glucocorticoides para el tratamiento de la diabetes para el tratamiento de la diabetes
IL155093A0 (en) 2000-09-29 2003-10-31 Glaxo Group Ltd Morpholin-acetamide derivatives for the treatment on inflammatory diseases
GB0031179D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Nitric oxide synthase inhibitors
US6484903B2 (en) 2001-01-09 2002-11-26 Riverwood International Corporation Carton with an improved dispensing feature in combination with a unique handle
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
GB0105360D0 (en) 2001-03-03 2001-04-18 Glaxo Group Ltd Chimaeric immunogens
EP1366025B1 (de) 2001-03-08 2007-06-27 Glaxo Group Limited Agonisten von beta-adrenorezeptoren
JP4143413B2 (ja) 2001-03-22 2008-09-03 グラクソ グループ リミテッド β２−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
ES2438985T3 (es) 2001-09-14 2014-01-21 Glaxo Group Limited Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
CN1555548A (zh) * 2001-09-20 2004-12-15 先锋株式会社 发光元件驱动电路
US20030235555A1 (en) * 2002-04-05 2003-12-25 David Shealey Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses
CA2472746A1 (en) 2002-01-14 2003-07-24 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them and uses thereof
JP4745609B2 (ja) 2002-01-22 2011-08-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア グルココルチコイドレセプターのための非ステロイド性リガンド、その組成物および使用
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
WO2003080675A2 (en) * 2002-03-22 2003-10-02 Amrad Operations Pty Ltd MONOCLONAL ANTIBODY AGAINST INTERLEUKIN-13 RECEPTOR ALPHA 1 (IL-13Rα1)
UA80120C2 (en) 2002-03-26 2007-08-27 Boehringer Ingelheim Pharma Glucocorticoid mimetics, pharmaceutical composition based thereon
CA2477764A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10215316C1 (de) 2002-04-02 2003-12-18 Schering Ag Chinolin- und Isochinolin-Derivate, ein pharmazeutisches Mittel und ihre Verwendung als Entzündungshemmer
DE60335869D1 (de) 2002-04-11 2011-03-10 Merck Sharp & Dohme 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
AU2003243189B2 (en) 2002-05-01 2008-01-24 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
SI1521733T1 (sl) 2002-07-08 2014-10-30 Pfizer Products Inc. Modulatorji glukokortikoidnega receptorja
ES2337679T3 (es) 2002-07-18 2010-04-28 Bristol-Myers Squibb Company Composiciones y procedimientos que implican el sitio ii de los receptores nucleares de hormonas.
WO2004009017A2 (en) 2002-07-18 2004-01-29 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
GB0216648D0 (en) 2002-07-18 2002-08-28 Lonza Biologics Plc Method of expressing recombinant protein in CHO cells
US20040219142A1 (en) * 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors
CA2496175A1 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
CN100387598C (zh) 2002-09-16 2008-05-14 葛兰素集团有限公司 吡唑并[3,4-b]吡啶化合物及其作为磷酸二酯酶抑制剂的用途
EP1542996A4 (de) 2002-09-20 2009-11-18 Merck & Co Inc OCTAHYDRO-2H-NAPHTOç1,2-F INDOL-4-CARBONSûUREAMIDDERIVATE ALS SELEKTIVE MODULATOREN DES GLUCOCORTICOIDREZEPTORS
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
US7790405B2 (en) * 2004-04-26 2010-09-07 Centocor, Inc. Solution phase biopanning method using engineered decoy proteins
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
US7501121B2 (en) * 2004-06-17 2009-03-10 Wyeth IL-13 binding agents

Also Published As

Publication number Publication date
US20070258979A1 (en) 2007-11-08
EP2436697A1 (de) 2012-04-04
ES2378173T3 (es) 2012-04-09
ES2456897T3 (es) 2014-04-23
PE20060376A1 (es) 2006-06-02
MA28726B1 (fr) 2007-07-02
ATE535545T1 (de) 2011-12-15
JP5102616B2 (ja) 2012-12-19
TWI307630B (en) 2009-03-21
NZ552063A (en) 2010-01-29
AU2005259025A1 (en) 2006-01-12
JP2008511542A (ja) 2008-04-17
RU2404192C2 (ru) 2010-11-20
CY1112372T1 (el) 2015-12-09
SG153878A1 (en) 2009-07-29
KR20070034609A (ko) 2007-03-28
AR049565A1 (es) 2006-08-16
DK1802658T3 (da) 2012-03-12
MX2007000026A (es) 2007-03-07
IL180152A0 (en) 2007-06-03
EP1802658B1 (de) 2011-11-30
US7807788B2 (en) 2010-10-05
US20110243928A1 (en) 2011-10-06
BRPI0512826A (pt) 2008-04-08
WO2006003407A3 (en) 2006-04-27
RU2007103826A (ru) 2008-08-10
HRP20120139T1 (hr) 2012-03-31
PL1802658T3 (pl) 2012-04-30
WO2006003407A2 (en) 2006-01-12
PT1802658E (pt) 2012-03-06
CA2571799A1 (en) 2006-01-12
EP1802658A2 (de) 2007-07-04
EP2436697B1 (de) 2014-03-05
TW200612985A (en) 2006-05-01
SI1802658T1 (sl) 2012-03-30
AU2005259025B2 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
NO20070189L (no) Immunoglobuliner
NO20082767L (no) Kimaere og humaniserte anti-humane IL-13 antistoffer
NO341523B1 (no) Benzoimidazol-2-ylpyrimidiner og -pyraziner som modulatorer av histamin H4-reseptoren, farmasøytisk sammensetning samt anvendelse
NO20082942L (no) Ligander som binder IL-4 og/eller IL-13
CY1120874T1 (el) Συνθεση αντισωματος ιντερλευκινης-13
NO20071312L (no) Bindinger som er monovalente for CD40L binding og framgangsmate for bruk
WO2008123999A3 (en) Anti-ige antibodies
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
NZ599875A (en) Human il-23 antigen binding proteins
NO20065487L (no) Modulering av immunglobulinproduksjon og atopiske forstyrrelser
WO2008097461A3 (en) Hepcidin and hepcidin antibodies
NO20083720L (no) Fremgangsmater og sammensetninger for antagonisme av RAGE
MXPA02011311A (es) Composicion novedosa.
WO2010017196A3 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
NO20073628L (no) Pyridoner som er nyttige som inhibitorer av kinaser
MY185813A (en) Factor xi antibodies and methods of use
WO2006077471A3 (en) Combining therapies targeting multiple toll-like receptors and use thereof
DK1572748T3 (da) Humaniseret antistof (H14.18) af muse-14.18-antistof der binder til GD2 og dets fusionsprotein med IL-2
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
MX340696B (es) Anticuerpos anti-c5a y metodos para usar los anticuerpos.
NO20090268L (no) Benzofuro- and benzothienopyrimidine modulators of the histamine H4 receptor
EA201892184A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора
UA130540C2 (uk) Композиція антитіла b7-h4
WO2018217918A3 (en) ANTI-LIGAND ANTI-CD40 THERAPEUTIC ANTIBODIES
WO2018129451A3 (en) Anti-fgfr antibodies and methods of use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application